Amate and OnabotulinumtoxinA. Combined together with the truth that the anti-CGRP monoclonal antibodies have, currently at this stage with a number of trials nevertheless ongoing, the highest number of patients studied d provided their great tolerability, these new agents are emerging, from a clinical point of view, as a promising treatment for chronic migraine.P2 Biomarkers of inflammation in sufferers with Chronic Migraine immediately after withdrawal from Medication Overuse: longitudinal changes and comparison with healthy subjects Licia Grazzi1, Emanuela Sansone1, Alberto Raggi2, Matilde Leonardi2, Emilio Ciusani3, Elena Corsini3, Giovanni D’Andrea4, Andrea Bolner4, Francisco Salgado-Garc five, Frank Andrasik5, Domenico D’Amico1 1 Headache and Neuroalgology Unit; Neurological Institute “C. Besta” IRCCS Foundation; Milan; 20133; Italy; 2Neurology, Public Overall health and Disability Unit; Neurological Institute “C. Besta” IRCCS Foundation; Milan; 20133; Italy; 3Laboratory of Clinical Pathology and Healthcare Genetic; Neurological Institute “C. Besta” IRCCS Foundation; Milan; 20133; Italy; 4 Investigation Innovation (R I); Padua; 35121; Italy; 5Department of Psychology; University of Memphis; Memphis, TN; 38152; USA Correspondence: Domenico D’Amico The Journal of Headache and Pain 2017, 18(Suppl 1):P2 Background Chronic Migraine (CM) is characterized by far more than 15 daysmonth for extra than 3 months, and is regularly connected towards the overuse of acute medications. In current years, non-pharmacological therapies have already been proposed and, among them, Mindfulness is one of the most promising1 and showed to be comparable to pharmacological prophylaxis2. It was also shown that sufferers undergoing pharmacological prophylaxis and Mindfulness sessions had comparable baseline levels for biomarkers and in element underwent substantial improvement3. Right here we aim to address improvement in biomarkers by comparing final results on sufferers with those of wholesome controls. Supplies and procedures Two group of sufferers, 1 getting pharmacological prophylaxis alone and one particular treated with six group session of Mindfulness-based coaching, have been followed-up at three, 6 and 12 months. We compared sufferers and control for white blood cell (WBC) count, neutrophils, total lymphocytes and lymphocyte subsets CD3, CD4, CD8, CD19 at each point with Mann-Whitney test. Results Data have been readily available for 34 sufferers (17 per group: no variations have been located cross-sectionally, and the longitudinal course was similar) and 34 controls. Compared to controls, patients reported greater baseline levels for WBC, neutrophils and lymphocyte subsets CD4. All levels, except lymphocyte subsets CD4, became related to that of controls in the third month, and CD4 became comparable at six months from withdrawal. Conclusions Some biomarkers of inflammation had been altered in patients with CM associated to medication overuse: from the third month after withdrawal patients show a reduction of inflammation which is maintained at 12 months. Pharmacological prophylaxis and Mindfulness showed comparable final results.References 1) Andrasik F, et al. Mindfulness and headache: A “new” old remedy, with new findings. Cephalalgia. 2016;36(12):1192-1205.EHF POSTER PRESENTATIONSP1 Anti-CGRP monoclonal antibodies for the treatment of chronic migraine: an overview of out there final results and comparison with the at present Bongkrekic acid manufacturer utilised prophylactics Fenne Vandervorst, Laura Van Deun, Jacques De Keyser, Jan Versijpt Department of Neurology, University Hospital Brussels, Brussels, Belgium.